A bulk drug substance, also known as an Active Pharmaceutical Ingredient (API), is the chemically active component intended to provide therapeutic effects in a finished pharmaceutical product. Unlike finished dosage forms, it is not formulated with excipients and is typically supplied in large quantities to drug manufacturers for final processing into tablets, capsules, injectables, or topical forms.
Bulk drug substances are the core therapeutic agents in every medicine. Their quality and consistency directly affect:
They represent a critical procurement point for CDMOs, generics manufacturers, and contract formulation partners worldwide.
These APIs are shipped globally in kilograms to metric ton volumes for secondary formulation and packaging.
There is no difference—bulk drug substance is simply another term for Active Pharmaceutical Ingredient (API), referring to the active compound before it’s formulated with excipients into a finished dosage form.
Yes. APIs for human use must be manufactured under ICH Q7 GMP guidelines and subject to regular audit.
No. They must be formulated with excipients into a finished dosage form (tablet, capsule, injection) before use.
Minimum includes CoA, DMF or CEP, stability data, residual solvent profile, and GMP compliance certification.
Yes. Pharmint supports RFQs for sterile-grade APIs, micronized particles, or customized specifications from qualified manufacturers.